Vedolizumab Injections for Ulcerative Colitis Treatment at Home

Understanding Vedolizumab for Ulcerative Colitis Treatment

Ulcerative colitis is an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. While treatment plans vary depending on severity, vedolizumab (Entyvio) is a biologic injection medication often prescribed for moderate to severe cases when other options have failed.

What is Vedolizumab?

Vedolizumab is in a medication class called integrin receptor antagonists. It works by targeting gut inflammation that damages the gastrointestinal tract’s lining in ulcerative colitis. By binding to receptors on white blood cells, vedolizumab stops these cells from moving out of the bloodstream and into inflamed intestinal tissues.

How is Vedolizumab Administered?

Vedolizumab is given by intravenous infusion typically every 8 weeks by a healthcare professional. The initial doses are given at week 0, week 2, and week 6. After that, maintenance doses are administered every 8 weeks for continual management of ulcerative colitis inflammation.

10 Key Facts About Vedolizumab Treatment

As a newly approved therapy for ulcerative colitis, vedolizumab is an exciting treatment option but requires proper understanding to use safely and effectively. Here are 10 key facts those considering vedolizumab injections should know.

1. Slower Onset But Long-Lasting

Compared to other biologics, vedolizumab has a slower onset of action taking 10-14 weeks to reach maximal effect. However, its long-lasting gut selectivity offers durable remission lasting at least 52 weeks for many patients.

2. Minimizing Infusion Reactions

Infusion-related reactions are uncommon with vedolizumab. However, your doctor may prescribe steroids, antihistamines, or antipyretics before the infusion to further reduce the small risk of reactions.

3. Managing Infections

Biologics like vedolizumab hinder immune response, so vigilance for infections during treatment is key. Notify your doctor immediately regarding fever, fatigue, cough, wounds not healing, or other infection signs.

4. No Evidence of PML Risk Yet

A rare brain infection called PML is a concern with some biologics. Fortunately, an extensive clinical study found no increased PML risk associated with vedolizumab use so far.

5. Supports Clinical Remission

In clinical trials, vedolizumab proved significantly more effective at inducing and maintaining steroid-free remission than placebo over 6-52 weeks among UC patients unresponsive to other treatments.

6. Consider Impact on Vaccines

Live vaccines should be avoided shortly before and during vedolizumab treatment. Be sure your vaccines are up-to-date per your doctor’s guidance prior to starting immunosuppressive therapy.

7. Potential for Oral Medication

An oral capsule formulation of vedolizumab is currently undergoing late-stage clinical testing. If approved, this could allow easier self-administration at home than the intravenous route.

8. Weigh Benefits vs. Skin Cancer Risks

A few cases of skin melanoma and Merkel cell carcinoma emerged in clinical trials. While rare, this signals the need to monitor skin changes closely and use sun protection during treatment.

9. Requires Ongoing Provider Partnership

Since vedolizumab is a newly approved drug with strict administration protocols and potential side effects, working closely with your healthcare team is critical for safe, effective treatment.

10. Offers Another Option When Others Fail

For those struggling to manage ulcerative colitis despite trying several other medications first, vedolizumab represents a much-needed alternative that can induce remission safely and durably when prior regimens fail.

Home Self-Injection Prospects in the Future

While vedolizumab currently requires intravenous infusion under medical supervision, that may eventually change. The convenience of home self-injection could vastly improve consistent access and patient quality of life. This possibility hinges on a few key factors:

Oral Formulation Approval

The oral capsule form undergoing late phase 3 trials may receive FDA approval in coming years. If proven effective with good absorption, safe oral dosing from home could enable self-management.

Subcutaneous Injection Research

Subcutaneous injection allows medication delivery into fat tissue below the skin. Researchers are also studying if vedolizumab can be effectively self-administered through subcutaneous injection using prefilled syringes.

Patient Training on Proper Technique

Home self-injection or oral medication for ulcerative colitis would require extensive patient training on sterile preparation, proper injection technique, sharps disposal, and signs of complications requiring prompt provider reporting.

Is Vedolizumab Right for You?

Vedolizumab offers noteworthy benefits but also involves risks requiring careful consideration with your doctor if other treatments fail. Here are a few key factors to help assess if vedolizumab is the right fit:

Failed Multiple Treatments First

Given its immunosuppressant effects and IV administration requirements, vedolizumab works best for patients not responding adequately to several other medications first.

Prospect of Durable Remission

The ability to induce steroid-free clinical remission lasting at least one year makes vedolizumab an attractive option for those needing prolonged disease control.

Commitment to Ongoing Monitoring

To mitigate adverse reaction and infection risks, vedolizumab treatment involves very close monitoring and partnership with your healthcare provider team long-term.

By understanding key aspects of therapy - like administration, effectiveness, side effects, and prerequisites - patients can forge a thoughtful, informed decision around using vedolizumab as part of their ulcerative colitis treatment plan when other medical options fail to control symptoms adequately.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.